1. Vlaminck, P. (2002). De 'schizofrenie' ontmanteld. Maandblad Geestelijke volksgezondheid, 57:342-363.
2. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders [DSM-IV-TR tm]. Washington, DC: American Psychiatric Association.
3. Haan, L. d. (2001). Patients' perspectives : subjective experiences and attitudes of patients with recent onset schizophrenia. Amsterdam: Universiteit van Amsterdam.
4. Os, J. v., Hanssen, M., Bijl, R. V., en Vollebergh, W. (2001). Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch.Gen.Psychiatry, 58:663-668.
5. National Institute of Mental Health (NIMH) (2002). Schizophrenia. National Institute of Mental Health (NIMH): www.nimh.nih.gov.
6. Walsh, E., Buchanan, A., en Fahy, T. (2002). Violence and schizophrenia: examining the evidence. Br.J.Psychiatry, 180:490-495.
7. National electronic Library for Health (NHS) (2002).Schizophrenia - basic. National electronic Library for Health (NHS): http://cebmh.warne.ox.ac.uk/cebmh/nelmh/schizophrenia.
8. Bijl, R. V. (1997). Schizofrenie. In: I.A.M.Maas, R.Gijsen, I.E.Lobbezoo and M.J.J.C.Poos (red.). Volksgezondheid Toekomst Verkenning 1997 I : de gezondheidstoestand: een actualisering, pp. 293-300. Amsterdam ; Utrecht ; Bilthoven: Elsevier : De Tijdstroom : Rijksinstituut voor Volksgezondheid en Milieu.
9. Wiersma, D. en De Jong, A. (1999). Schizofrenie en aanverwante stoornissen. In: A.d.Jong, W.v.d.Brink and J.Ormel (red.). Handboek psychiatrische epidemiologie, Maarssen: Elsevier/De Tijdstroom.
10. Bhugra, D., Hilwig, M., Hossein, B., Marceau, H., Neehall, J., Leff, J., Mallett, R., en Der, G. (1996). First-contact incidence rates of schizophrenia in Trinidad and one-year follow-up. Br.J.Psychiatry, 169:587-592.
11. American Psychiatric Association (2002). Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association: www.psych.org/clin_res/pg_schizo.cfm
12. Royal Australian and New Zealand College of Psychiatrists (2002). Clinical practice guidelines for the treatment of schizophrenia (concept). (ongepubliceerd)
13. Ormel, J., Neeleman, J., en Wiersma, D. (2001). Determinanten van psychische ongezondheid; implicaties voor onderzoek en beleid. Tijdschrift voor Psychiatrie, 43:245-257.
14. Byrne, M., Agerbo, E., en Mortensen, P. B. (2002). Family history of psychiatric disorders and age at first contact in schizophrenia: an epidemiological study. Br.J.Psychiatry Suppl, 43:s19-s25
15. Selten, J. P., Veen, N., Feller, W., Blom, J. D., Schols, D., Camoenie, W., Oolders, J., van, d., V, Hoek, H. W., Rivero, V. M., van der, G. Y., en Kahn, R. (2001). Incidence of psychotic disorders in immigrant groups to The Netherlands. Br.J.Psychiatry, 178:367-372.
16. Cannon, M., Jones, P. B., en Murray, R. M. (2002). Obstetric complications and schizophrenia: historical and meta-analytic review. Am.J.Psychiatry, 159:1080-1092.
17. Rigter, H., Laar, M. v., Rigter, S., en Kilmer, B. (2002). Cannabis: Feiten en cijfers anno 2002. Utrecht: Bureau NDM.
18. Os, J. v., Bak, M., Hanssen, M., Bijl, R. V., De Graaf, R., en Verdoux, H. (2002). Cannabis use and psychosis: a longitudinal population-based study. Am.J.Epidemiol., 156:319-327.
19. Reinking, D. P., Wolf, J. R., en Kroon, H. (2001). Hoge prevalentie van psychische stoornissen en verslavingsproblemen bij daklozen in de stad Utrecht. Ned.Tijdschr.Geneeskd., 145:1161-1166.
20. Reinking, D., Nicholas, S., en Leiden, I. v. (2001). Daklozen in Den Haag : onderzoek naar omvang en kenmerken van de daklozenpopulatie. Utrecht: Trimbos-instituut.
21. Wiersma, D., Wanderling, J., Dragomirecka, E., Ganev, K., Harrison, G., An Der, H. W., Nienhuis, F. J., en Walsh, D. (2000). Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol.Med., 30:1155-1167.
22. Haan, L. d., Timmer, T., Linszen, D. H., Lenior, M. E., en Wouters, L. (2001). Het beloop van schizofrenie gedurende vijf jaar na een eerste opname, in de westerse wereld. Een meta-analyse. Tijdschrift voor Psychiatrie, 43:559-565.
23. Drake, R. E., Essock, S. M., Shaner, A., Carey, K. B., Minkoff, K., Kola, L., Lynde, D., Osher, F. C., Clark, R. E., en Rickards, L. (2001). Implementing dual diagnosis services for clients with severe mental illness. Psychiatr.Serv., 52:469-476.
24. Herrman, H., Hawthorne, G., en Thomas, R. (2002). Quality of life assessment in people living with psychosis. Soc.Psychiatry Psychiatr.Epidemiol., 37:510-518.
25. Maas, P. J. en Kramers, P. G. N. (1997). Volksgezondheid Toekomst Verkenning 1997 III : gezondheid en levensverwachting gewogen. Amsterdam ; Utrecht ; Bilthoven: Elsevier : De Tijdstroom : Rijksinstituut voor Volksgezondheid en Milieu.
26. Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., en Lehtinen, V. (2001). Mental disorders and cause-specific mortality. Br.J.Psychiatry, 179:498-502.
27. Brown, S., Inskip, H., en Barraclough, B. (2000). Causes of the excess mortality of schizophrenia. Br.J.Psychiatry, 177:212-217.
28. National Confidential Inquiry into Suicide and Homicide by People with Mental Illness (2001). Safety first. Five-year report of the National Confidential Inquiry into Homicide by People with Mental Illness . London: Department of Health.
29. Polder, J. J., Takken, J., Meerding, W. J., Kommer, G. J., en Stokx, L. J. (2002). Kosten van ziekten in Nederland: de zorgeuro ontrafeld. Bilthoven: RIVM.
30. Knapp, M., Chisholm, D., Leese, M., Amaddeo, F., Tansella, M., Schene, A., Thornicroft, G., Vazquez-Barquero, J. L., Knudsen, H. C., en Becker, T. (2002). Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatr.Scand., 105:42-54.
31. Heinrichs, R. W. (2001). In search of madness. Schizophrenia and neuroscience. Oxford: Oxford University Press.
32. Gezondheidsraad (1999). Opsporing en behandeling van adolescenten met schizofrenie. Publicatie 1999/08. Den Haag: Gezondgheidsraad.
33. McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., Adlard, S., en Jackson, H. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch.Gen.Psychiatry, 59:921-928.
34. McEvoy, J. P. e. a. (1999). The Expert Consensus Guideline Series: Treatment of schizophrenia 1999. Journal of Clinical Psychiatry 1999, 60(suppl 11):
35. Canadian Psychiatric Association (2002). Canadian practical guidelines for the treatment of schizophrenia. www.cpa-apc.org.
36. Lawrie, S. M., McIntosh, A. M., en Rao, S. (2000). Critical appraisal for psychiatry. Edinburgh: Churchill Livingstone.
37. Thornley, B., Adams, C. E., en Awad, G. (2000). Chlorpromazine versus placebo for schizophrenia. Cochrane.Database.Syst.Rev., CD000284
38. Joy, C. B., Adams, C. E., en Lawrie, S. M. (2001). Haloperidol versus placebo for schizophrenia. Cochrane.Database.Syst.Rev., CD003082
39. Sultana, A. en McMonagle, T. (2000). Pimozide for schizophrenia or related psychoses. Cochrane.Database.Syst.Rev., CD001949
40. Soares, B. G., Fenton, M., en Chue, P. (2000). Sulpiride for schizophrenia. Cochrane.Database.Syst.Rev., CD001162
41. Sultana, A., Reilly, J., en Fenton, M. (2000). Thioridazine for schizophrenia. Cochrane.Database.Syst.Rev., CD001944
42. Wahlbeck, K., Cheine, M., en Essali, M. A. (2000). Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane.Database.Syst.Rev., CD000059
43. Duggan, L., Fenton, M., Dardennes, R. M., El Dosoky, A., en Indran, S. (2000). Olanzapine for schizophrenia. Cochrane.Database.Syst.Rev., CD001359
44. Srisurapanont, M., Disayavanish, C., en Taimkaew, K. (2000). Quetiapine for schizophrenia. Cochrane.Database.Syst.Rev., CD000967
45. Kennedy, E., Song, F., Hunter, R., Clarke, A., en Gilbody, S. (2000). Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane.Database.Syst.Rev., CD000440
46. Joy, C. B., Mumby-Croft, R., en Joy, L. A. (2000). Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia. Cochrane.Database.Syst.Rev., CD001257
47. Tharyan, P. en Adams, C. E. (2002). Electroconvulsive therapy for schizophrenia. Cochrane.Database.Syst.Rev., CD000076
48. Cormac, I., Jones, C., en Campbell, C. (2002). Cognitive behaviour therapy for schizophrenia. Cochrane.Database.Syst.Rev., CD000524
49. Pilling, S., Bebbington, P., Kuipers, E., Garety, P., Geddes, J., Orbach, G., en Morgan, C. (2002). Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol.Med., 32:763-782.
50. Mcintosh, A. en Lawrie, S. (2002). Schizophrenia. In: S.Barton (red.). Clinicial Evidence. Mental Health. The international source of the best available evidence for mental health care., pp. 110-131. London: BMJ Publishing Group.
51. Zygmunt, A., Olfson, M., Boyer, C. A., en Mechanic, D. (2002). Interventions to improve medication adherence in schizophrenia. Am.J.Psychiatry, 159:1653-1664.
52. Geddes, J. (2002). Prevention of relapse in schizophrenia. N.Engl.J.Med., 346:56-58.
53. Quraishi, S. en David, A. (2000). Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane.Database.Syst.Rev., CD001470
54. Adams, C. E. en Eisenbruch, M. (2000). Depot fluphenazine for schizophrenia. Cochrane.Database.Syst.Rev., CD000307
55. Quraishi, S. en David, A. (2000). Depot fluspirilene for schizophrenia. Cochrane.Database.Syst.Rev., CD001718
56. Quraishi, S. en David, A. (2000). Depot haloperidol decanoate for schizophrenia. Cochrane.Database.Syst.Rev., CD001361
57. Quraishi, S. en David, A. (2000). Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane.Database.Syst.Rev., CD001717
58. Quraishi, S. en David, A. (2001). Depot pipothiazine palmitate and undecylenate for schizophrenia. Cochrane.Database.Syst.Rev., CD001720
59. Coutinho, E., Fenton, M., en Quraishi, S. (2000). Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane.Database.Syst.Rev., CD001164
60. Pekkala, E. en Merinder, L. (2002). Psychoeducation for schizophrenia. Cochrane.Database.Syst.Rev., CD002831
61. Gaag, M. v. d. (2002). Evidence-based psychiatrische rehabilitatie bij schizofrenie en aanverwante psychosen. ??: ??
62. Scottish Intercollegiate Guidelines Network (SIGN) (1998). Psychosocial interventions in the management of schizophrenia. www.sign.ac.uk/guidelines/fulltext/30/index.html
63. Pharoah, F. M., Mari, J. J., en Streiner, D. (2000). Family intervention for schizophrenia. Cochrane.Database.Syst.Rev., CD000088
64. Malmberg, L. en Fenton, M. (2000). Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. Cochrane.Database.Syst.Rev., CD001360
65. Hayes, R. L. en McGrath, J. J. (2000). Cognitive rehabilitation for people with schizophrenia and related conditions. Cochrane.Database.Syst.Rev., CD000968
66. Pilling, S., Bebbington, P., Kuipers, E., Garety, P., Geddes, J., Martindale, B., Orbach, G., en Morgan, C. (2002). Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol.Med., 32:783-791.
67. Marshall, M. en Lockwood, A. (2000). Assertive community treatment for people with severe mental disorders. Cochrane.Database.Syst.Rev., CD001089
68. Joy, C. B., Adams, C. E., en Rice, K. (2000). Crisis intervention for people with severe mental illnesses. Cochrane.Database.Syst.Rev., CD001087
69. Johnstone, P. en Zolese, G. (2000). Length of hospitalisation for people with severe mental illness. Cochrane.Database.Syst.Rev., CD000384
70. Marshall, M., Crowther, R., Almaraz-Serrano, A. M., en Tyrer, P. (2001). Day hospital versus out-patient care for psychiatric disorders. Cochrane.Database.Syst.Rev., CD003240
71. Sailas, E. en Fenton, M. (2000). Seclusion and restraint for people with serious mental illnesses. Cochrane.Database.Syst.Rev., CD001163
72. Mellman, T. A., Miller, A. L., Weissman, E. M., Crismon, M. L., Essock, S. M., en Marder, S. R. (2001). Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms. Psychiatr.Serv., 52:619-625.
73. Quraishi, S., David, A., en Adams, C. E. (2000). Depot bromperidol decanoate for schizophrenia. Cochrane.Database.Syst.Rev., CD001719
74. Adams, C. (1999). Drug treatments for schizophrenia. Effective Health Care, 5:
75. Leucht, S., Pitschel-Walz, G., Engel, R. R., en Kissling, W. (2002). Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am.J.Psychiatry, 159:180-190.
76. Bagnall, A., Lewis, R. A., en Leitner, M. L. (2000). Ziprasidone for schizophrenia and severe mental illness. Cochrane.Database.Syst.Rev., CD001945
77. Fenton, M., Morris, S., De Silva, P., Bagnall, A., Cooper, S. J., Gammelin, G., en Leitner, M. (2000). Zotepine for schizophrenia. Cochrane.Database.Syst.Rev., CD001948
78. Leucht, S., Pitschel-Walz, G., Abraham, D., en Kissling, W. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr.Res., 35:51-68.
79. Tuunainen, A., Wahlbeck, K., en Gilbody, S. M. (2000). Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane.Database.Syst.Rev., CD000966
80. McGrath, J. J. en Soares, K. V. (2000). Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane.Database.Syst.Rev., CD000459
81. Gilbody, S. M., Bagnall, A. M., Duggan, L., en Tuunainen, A. (2000). Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane.Database.Syst.Rev., CD002306
82. Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., en Weiden, P. J. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am.J.Psychiatry, 156:1686-1696.
83. Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S. S., Magder, L. S., Kreyenbuhl, J., Revicki, D. A., en Buchanan, R. W. (2002). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ, 325:243
84. Geddes, J., Freemantle, N., Harrison, P., en Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321:1371-1376.
85. Csernansky, J. G., Mahmoud, R., en Brenner, R. (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N.Engl.J.Med., 346:16-22.
86. Leslie, D. L. en Rosenheck, R. A. (2002). From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am.J.Psychiatry, 159:1534-1540.
87. Fischer, E. P., Shumway, M., en Owen, R. R. (2002). Priorities of consumers, providers, and family members in the treatment of schizophrenia. Psychiatr.Serv., 53:724-729.
88. McMonagle, T. en Sultana, A. (2000). Token economy for schizophrenia. Cochrane.Database.Syst.Rev., CD001473
89. Dixon, L., McFarlane, W. R., Lefley, H., Lucksted, A., Cohen, M., Falloon, I., Mueser, K., Miklowitz, D., Solomon, P., en Sondheimer, D. (2001). Evidence-based practices for services to families of people with psychiatric disabilities. Psychiatr.Serv., 52:903-910.
90. Turkington, D., Kingdon, D., en Turner, T. (2002). Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. Br.J.Psychiatry, 180:523-527.
91. Mueser, K. T., Corrigan, P. W., Hilton, D. W., Tanzman, B., Schaub, A., Gingerich, S., Essock, S. M., Tarrier, N., Morey, B., Vogel-Scibilia, S., en Herz, M. I. (2002). Illness management and recovery: a review of the research. Psychiatr.Serv., 53:1272-1284.
92. Ley, A., Jeffery, D. P., McLaren, S., en Siegfried, N. (2000). Treatment programmes for people with both severe mental illness and substance misuse. Cochrane.Database.Syst.Rev., CD001088
93. Dickey, B., Normand, S. L., Weiss, R. D., Drake, R. E., en Azeni, H. (2002). Medical morbidity, mental illness, and substance use disorders. Psychiatr.Serv., 53:861-867.
94. Catty, J., Burns, T., en Comas, A. (2001). Day centres for severe mental illness. Cochrane.Database.Syst.Rev., CD001710
95. Nicol, M. M., Robertson, L., en Connaughton, J. A. (2000). Life skills programmes for chronic mental illnesses. Cochrane.Database.Syst.Rev., CD000381
96. Bond, G. R., Becker, D. R., Drake, R. E., Rapp, C. A., Meisler, N., Lehman, A. F., Bell, M. D., en Blyler, C. R. (2001). Implementing supported employment as an evidence-based practice. Psychiatr.Serv., 52:313-322.
97. Marshall, M., Gray, A., Lockwood, A., en Green, R. (2000). Case management for people with severe mental disorders. Cochrane.Database.Syst.Rev., CD000050
98. Tyrer, P., Coid, J., Simmonds, S., Joseph, P., en Marriott, S. (2000). Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality. Cochrane.Database.Syst.Rev., CD000270
99. Schizofrenie Platform (2000). Verdeelde aandacht, gedeelde zorg : van knelpunten naar kwaliteit in de zorg voor patiënten met schizofrenie. Montfoort: Schizofrenie Platform.
100. Schizofrenie Stichting Nederland (2001). Met het oog op beter, het vervolg. Soesterberg: Schizofrenie Stichting Nederland.
101. Ypsilon (2002). Vrijwilligheid en professionaliteit: de resultaten. Jaarverslag 2001. Rotterdam: Ypsilon.
102. M.J.J.C. Poos, J.M. Smit, J. Groen, G.J. Kommer, L.C.J. Slobbe (2008). Kosten van Ziekten in Nederland 2005. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu. www.kostenvanziekten.nl.
103. Graaf, de, R., Ten Have, M., Van Dorsselaer, S. (2010). NEMESIS-2: De psychische gezondheid van de Nederlandse bevolking. Opzet en eerste resultaten. Utrecht: Trimbos-instituut.
